Edition:
United States

FibroGen Inc (FGEN.OQ)

FGEN.OQ on NASDAQ Stock Exchange Global Select Market

57.50USD
3:59pm EST
Change (% chg)

$1.30 (+2.31%)
Prev Close
$56.20
Open
$56.15
Day's High
$57.60
Day's Low
$55.15
Volume
126,816
Avg. Vol
196,608
52-wk High
$63.00
52-wk Low
$22.80

Chart for

About

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.... (more)

Overall

Beta: --
Market Cap(Mil.): $4,619.50
Shares Outstanding(Mil.): 82.20
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 192.73 16.31
EPS (TTM): -- -- --
ROI: -- -0.67 35.74
ROE: -- -3.38 17.71

BRIEF-Fibrogen Inc reports Q3 loss per share $0.50

* Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S

Nov 08 2017

BRIEF-Fibrogen announces acceptance by china FDA of roxadustat NDA for treatment of anemia associated with dialysis and non-dialysis kidney disease

* Fibrogen announces acceptance by china FDA of roxadustat new drug application (NDA) for treatment of anemia associated with dialysis and non-dialysis chronic kidney disease (CKD)

Oct 18 2017

BRIEF-Fibrogen's ‍Pamrevlumab was well tolerated with no safety risks

* ‍Announced results from co's phase 2b randomized, double-blind, placebo-controlled study in patients with idiopathic pulmonary fibrosis​

Sep 13 2017

Earnings vs. Estimates